FOSCARNET PRESCRIBING INFORMATION PDF

are concise point-of-care prescribing, dosing and administering information to Prior to the initial foscarnet infusion, establish diuresis by administering Prehydrate with mL NS or D5W before first infusion to decrease risk for nephrotoxicity. See prescribing information for dose adjustments for CrCl < Group: antiviral. Solution for injection, 24 mg/ml ml, ml [non-EDL]. General information. Foscarnet is a non-nucleoside pyrophosphate analogue given.

Author: Tauzragore Murg
Country: Angola
Language: English (Spanish)
Genre: Marketing
Published (Last): 6 April 2006
Pages: 321
PDF File Size: 16.31 Mb
ePub File Size: 11.16 Mb
ISBN: 115-4-99511-204-7
Downloads: 7000
Price: Free* [*Free Regsitration Required]
Uploader: Shaktinris

Gadobenic acid The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Gadobenic acid.

Browse Drugs and Medicines.

Oxolinic acid The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Oxolinic acid. Your doctor may not want you to receive foscarnet injection. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as solifenacin. Dibekacin The risk or severity of nephrotoxicity can be increased when Dibekacin is combined with Foscarnet.

Prescrbiing carbonate Foscarnet may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. Cefotetan The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Foscarnet. Conjugated estrogens Foscarnet may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.

Pasireotide The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Pasireotide. If these drugs must be coadministered, appropriate cardiovascular monitoring precautions should be considered, such as the monitoring of electrolytes and ECGs at baseline and periodically during treatment.

  CAPTIVE OF MY DESIRES JOHANNA LINDSEY PDF

An antiviral agent incormation in the treatment of cytomegalovirus retinitis.

Foscarnet – DrugBank

Nateglinide Foscarnet may decrease the excretion rate of Nateglinide which could result in a higher serum level. Penbutolol Foscarnet may decrease the excretion rate of Penbutolol which could result in a higher serum level. Ranitidine Foscarnet may decrease the excretion rate of Ranitidine which could result in a higher serum level.

Vorinostat therapy is also associated with a risk of QT prolongation. Methyldopa Foscarnet may decrease the excretion rate of Methyldopa which could result in a higher serum level.

Minor Concurrent use of foscarnet and prescrbiing, ZDV may be associated with a higher incidence of anemia; clinicians should follow normal recommendations for blood count monitoring and other parameters. Mycobacterium avium complex MAC. Fenproporex Foscarnet may decrease the excretion rate of Fenproporex which could result in a higher serum level. Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Foscarnet.

Therefore, foscarnet should only be used in pregnancy if the potential benefits outweigh the risks to the foetus.

PDR Search

Efficacy of Foscarnwt maintenance therapy following induction therapy of aciclovir unresponsive HSV infections has not been established. Azosemide Azosemide may decrease the excretion rate of Foscarnet which could result in a higher serum level.

Dosulepin The risk or severity of Focarnet prolongation can be increased when Foscarnet is combined with Dosulepin. Azatadine The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Azatadine.

  ARABSAT CHANNEL LIST PDF

Fingolimod has not been studied in patients treated with drugs that prolong foscarneh QT interval, but drugs that prolong the QT interval have been associated with cases of TdP in patients with bradycardia.

Emtricitabine Roscarnet may decrease the excretion rate of Emtricitabine which could result in a higher serum level. Severe Dronedarone administration is associated with a dose-related increase in the QTc interval.

Dexchlorpheniramine The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dexchlorpheniramine. Ceftezole The risk or severity of nephrotoxicity can be increased when Ceftezole is combined with Foscarnet.

Tetrabenazine causes a small increase in the corrected QT interval QTc. Also, concurrent use may result in additive nephrotoxicity. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as olanzapine.

Failure to do so may result in local irritation. Fendiline The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Fendiline. Chromium Foscarnet may decrease the excretion rate of Chromium which could result in a higher serum level. In compliant patients, oral hydration with similar hydration regimens has been used. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Foscarnet.

Mifepristone has been associated with dose-dependent prolongation of the QT interval.

Author: admin